In the IMMUNOTARGET registry, in 16 patients with RET fusion + NSCLC treated with ICIs (second-line or further setting), the ORR was 6% with a mPFS of 2.1 months [41]. The gene discussed is RET; the disease is non-small cell lung carcinoma.